Listeria monocytogenes bacteriophages and uses thereof
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-8685697-B1
Publication Date
2014-04-01
Expiration Date
Abstract
The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Listeria species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Listeria species in various settings (e.g., food safety, sanitation, probiotics).
Core Innovation
The document describes isolated lytic bacteriophages LMSP-25, LMTA-34, LMTA-57, LMTA-94, and LMTA-148, each deposited under specified ATCC Accession Numbers. Each isolated bacteriophage has lytic activity against Listeria strains, and variants thereof retain the phenotypic characteristics of the corresponding bacteriophage and also have lytic activity against Listeria strains. The document characterizes progeny and variants in relation to phenotypic and lytic specificity, including RFLP profiling.
The document further covers progeny and variants, including isolated progeny having RFLP DNA profiles substantially equivalent to the profile of the deposited bacteriophage. In addition, it describes derivatives of the bacteriophage that comprise nucleic acids and/or genes, gene expression products, and/or structural components. The derivatives are described as phage derivatives that retain relevant lytic specificity and relate to the deposited bacteriophages.
The document also includes compositions that include at least one of the isolated bacteriophages and formulations for broader use. It presents application contexts for controlling Listeria, including food and food-processing environments, and describes other use contexts for controlling or eradicating Listeria, including medical/veterinary and animal husbandry settings.
Claims Coverage
The partial content provided includes two independent claims: one directed to specific isolated lytic bacteriophages and their variants retaining phenotypic characteristics, and another directed to a method for reducing food-borne illnesses caused by Listeria strains via contacting food with a lytic, growth-inhibiting phage composition. Across the independent claims, the main inventive features include defined deposited phage identities with lytic activity against Listeria strains, variants retaining phenotypic characteristics and lytic activity, and method use involving contacting food products with a microbial growth inhibiting effective amount of the phage composition.
Deposited isolated lytic bacteriophages and variants retaining phenotypic characteristics
An isolated bacteriophage LMSP-25 deposited under ATCC Accession No. PTA-8353, LMTA-34 deposited under ATCC Accession No. PTA-8354, LMTA-57 deposited under ATCC Accession No. PTA-8355, LMTA-94 deposited under ATCC Accession No. PTA-8356, or LMTA-148 deposited under ATCC Accession No. 8357, said bacteriophage having lytic activity against Listeria strains, and variants thereof, wherein said variants retain the phenotypic characteristics of said bacteriophage and wherein said bacteriophage and variants thereof have lytic activity against Listeria strains.
Reducing incidence of food borne illnesses by contacting food with a growth inhibiting lytic bacteriophage composition
A method for the reduction in the incidence of food borne illnesses caused by Listeria strains comprising contacting a food product or products with a microbial growth inhibiting effective amount of a bacteriophage composition comprising at least one of the isolated bacteriophage LMSP-25 deposited under ATCC Accession No. PTA-8353, LMTA-34 deposited under ATCC Accession No. PTA-8354, LMTA-57 deposited under ATCC Accession No. PTA-8355, LMTA-94 deposited under ATCC Accession No. PTA-8356, or LMTA-148 deposited under ATCC Accession No. 8357, said bacteriophage having lytic activity against Listeria strains, and variants thereof, wherein said variants retain the phenotypic characteristics of said bacteriophage and wherein said bacteriophage and variants thereof have lytic activity against Listeria strains.
Overall, the claim coverage centers on specific deposited isolated lytic bacteriophages against Listeria strains and variants that retain phenotypic characteristics and lytic activity, and on a method that reduces food-borne illness incidence by contacting food products with a microbial growth inhibiting effective amount of a lytic bacteriophage composition containing those deposited phages and variants.
Stated Advantages
Reduces the incidence of food borne illnesses caused by Listeria strains.
Documented Applications
Controlling or eradicating Listeria in food and food-processing environments, including sanitation of equipment/surfaces.
Preventing Listeria growth and preserving foods at specified growth-inhibiting PFU ranges.
Removing undesirable/antibiotic-resistant pathogens in medical/veterinary and animal husbandry settings.
Preventing and treating human/animal diseases and infections caused by Listeria.
Detection and epidemiological typing systems using phage or phage derivatives, including reporter/luciferase and ATP/adenosine kinase release readouts.
Interested in licensing this patent?